Loading...
•
Mar 31, 2021
Vera Q1 2021 Earnings Report
Vera Therapeutics reported financial results for the first quarter ended March 31, 2021, and provided a corporate update.
Key Takeaways
Vera Therapeutics reported a net loss of $4.7 million for the first quarter of 2021. The company's cash and cash equivalents were approximately $49.5 million as of March 31, 2021.
Initiated the Phase 2b ORIGIN clinical trial of atacicept in patients with IgA nephropathy (IgAN).
Appointed Celia Lin, MD, as Chief Medical Officer.
Appointed Tad Thomas, PhD, as Senior Vice President and Head of Product Development and Manufacturing.
Completed an initial public offering with net proceeds of approximately $48.4 million in May 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...